PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|August 31, 2017
Avista Pharma Appoints Eric Evans as CFO
Author(s)Pharmaceutical Technology Editors
Avista Pharma has appointed Eric Evans as CFO.
Advertisement
On Aug. 29, 2017, Avista Pharma appointed Eric Evans as CFO effective Aug. 28, 2017. Evans will oversee the company’s finance, purchasing and information technology operations. With more than 30 years of experience, Mr. Evans has held leadership roles in companies across the pharmaceutical and contract service sectors, including CFO of Mayne Pharma, AAIPharma Services, and Patheon. He also held positions as vice president and controller for Novartis and Sandoz.
“Eric has a proven track record of providing leadership in financial and operational strategies in growth organizations,” said Patrick Walsh, CEO of Avista Pharma, in a company press release. “His experience will ensure continued success for the company and our clients, and I am delighted to be working with him again.”
Source:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement